SPONSOR
Tianjin Medical University Cancer Institute and Hospital
Total Trials
16
Recruiting
16
Phases
Phase 2, Phase 4, Phase 1, Phase 2
Conditions studied: Cervical CancersLung CancersRadiation Treatment for TumorsResectable Esophageal Squamous Cell CarcinomaNSCLCEsophageal CancerPrimary Liver CancerDiffuse Large B-Cell Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-RefractoryDiffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital is a clinical research sponsor with 16 registered studies on ClinicalTrials.gov, of which 16 are actively recruiting participants. Research covers conditions including Cervical Cancers, Lung Cancers, Radiation Treatment for Tumors, Resectable Esophageal Squamous Cell Carcinoma.
The trial portfolio spans Phase 2, Phase 4, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Tianjin Medical University Cancer Institute and Hospital
How many clinical trials has Tianjin Medical University Cancer Institute and Hospital sponsored?
ClinicalMetric currently tracks 16 clinical trials sponsored by Tianjin Medical University Cancer Institute and Hospital, of which 16 are actively recruiting participants. These trials cover conditions including Cervical Cancers, Lung Cancers, Radiation Treatment for Tumors. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Tianjin Medical University Cancer Institute and Hospital research focus on?
Tianjin Medical University Cancer Institute and Hospital clinical trials span Cervical Cancers, Lung Cancers, Radiation Treatment for Tumors, Resectable Esophageal Squamous Cell Carcinoma, NSCLC, and additional conditions. The research pipeline includes Phase 2, Phase 4, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Tianjin Medical University Cancer Institute and Hospital clinical trial?
To participate in a Tianjin Medical University Cancer Institute and Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tianjin Medical University Cancer Institute and Hospital trials with current recruitment status updated daily.
Clinical Trials by Tianjin Medical University Cancer Institute and Hospital
NCT06727617 Phase 2
Recruiting
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
Cervical Cancers
NCT06775678 Phase 2
Recruiting
Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
Lung Cancers
NCT07457528 Phase 2
Recruiting
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Resectable Esophageal Squamous Cell Carcinoma
NCT06221670 Phase 2
Recruiting
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
NSCLC
NCT06061146 Phase 2
Recruiting
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
Esophageal Cancer
NCT06766643 Phase 2
Recruiting
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
Primary Liver Cancer
NCT06570447 Phase 2
Recruiting
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Diffuse Large B-Cell Lymphoma-Recurrent
NCT07397832 Phase 2
Recruiting
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05035147 Phase 4
Recruiting
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Pancreatic Cancer
NCT07099274 Phase 2
Recruiting
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
HCC
NCT07304739 Phase 2
Recruiting
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Non Small Cell Lung Cancer
NCT07012798 Phase 2
Recruiting
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
NCT07058948 Phase 2
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Solid Cancers
NCT06454448 Phase 1, Phase 2
Recruiting
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Adebrelimab (SHR-1316)
NCT07162506 Phase 2
Recruiting
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Esophageal Cancer
NCT04631770
Recruiting
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
Lung Neoplasms
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology